# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to ...
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to ...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60...
Precision BioSciences (NASDAQ:DTIL) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of...
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to ...